NFKB1 and pancreatic neoplasm: Previous studies have reported that TAK1 increases chemoresistance via the NF-κB pathway and targeting TAK1 has been shown to be a potential therapeutic approach to reducing the chemoresistance of pancreatic cancer [16, 28].